非小细胞肺癌免疫检查点抑制剂治疗进展

Progress in the Treatment of Non⁃small Cell Lung Cancer with Immune Checkpoint Inhibitors

肺癌是全球范围内发病率及死亡率极高的恶性肿瘤,其中以非小细胞肺癌(non-small cell lung cancer,NSCLC)最为常见。NSCLC的传统治疗主要依靠化学药物,近年来免疫治疗成为NSCLC治疗的热点,并取得了令人瞩目的进展。大量新型生物免疫制剂被开发并应用于临床,其中免疫检查点抑制剂的应用最广、疗效最为肯定。本文将对近年NSCLC免疫治疗生物标志物研究现状及进展进行阐述,以期提高免疫治疗精准度,更好地指导NSCLC患者的个体化治疗。

Lung cancer is a malignant tumor with high incidence rate and mortality worldwide.Non⁃small cell lung cancer(NSCLC)is the most common malignancy.The traditional treatment of NSCLC mainly depends on chemical drugs.In recent years,immunotherapy has become a hot spot in the treatment of NSCLC and made remarkable progress.The overall objective remission rate of immunotherapy for NSCLC patients is about 20%.A large number of new biological immune agents have been developed and applied in clinic.Among them,immune checkpoint inhibitor(ICI)has the widest application and the most positive effect on NSCLC.This paper summari⁃zes the research status and progress of immunotherapy biomarkers of NSCLC in recent years,with the hope of im⁃proving the accuracy of immunotherapy and better guiding individualized treatment of NSCLC patients.